Semaglutide Improves Outcomes in Patients with Obesity, HFpEF, and Type 2 Diabetes

In a randomized, controlled trial, semaglutide resulted in greater weight loss, improved symptoms, and fewer serious adverse events compared with placebo.

Obesity and type 2 diabetes are common comorbidities in patients with heart failure with preserved ejection fraction (HFpEF). Currently, there are no FDA-approved therapies that specifically treat all three conditions at the same time; however, semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has the potential to do so.

In an industry-funded trial (NCT04916470), investigators randomized 616 adults with HFpEF (left ventricular ejection fraction ≥45%), body-mass index >30, and type 2 diabetes to receive semaglutide (2.4 mg) or matching placebo once weekly for 52 weeks. They assessed dual primary endpoints of change in heart failure symptoms via Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS; range, 0–…

Reviewing Author

Karol E. Watson, MD, PhD, FACC

Disclosures

Consultant/Advisory BoardBoehringer Ingelheim; Amgen; Novartis; Lilly; Amarin

Speaker’s BureauBoehringer Ingelheim

Grant/Research SupportNIH

Editorial BoardsCirculation (Associate Editor)